Plain-English translation of NCT03174977 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers want to understand exactly where raltegravir, an HIV medication, goes in your body and how it spreads to different tissues and organs. This pilot study uses a radioactive version of the medication combined with advanced imaging (a PET/MRI scan) to map the medication's journey. The goal is to better understand how this treatment works in real patients.
Even though this medication is already approved and used to treat HIV, doctors want to learn more about exactly how it moves through the body and which tissues it reaches. This knowledge could help improve treatment plans and ensure the medication is working as effectively as possible in different parts of the body.
You would receive a small injection of a radioactive form of the medication through your IV, then undergo a PET/MRI imaging scan (a painless scanning procedure that takes pictures of how the medication spreads through your body). This is a pilot study with a small group of 10 people, and the entire process happens during a single visit. No ongoing appointments or long-term commitment is required beyond this initial scan day.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
University of California, San Francisco
Collaborators
Merck Sharp & Dohme LLC
Enrollment target
~10 participants
Started
April 2018
Primary completion
November 2024
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Timothy J Henrich, MD
University of California, San Francisco